genotropin 12mg

genotropin 12mg is a strong metabolic hormone that plays an important role in the metabolism of lipids, carbohydrates and proteins. genotropin 12mg  is produced in Escherichia coli cells by recombinant DNA technology. In children with endogenous growth hormone deficiency,  accelerates linear skeletal growth and growth rate. In both adults and children,  supports normal body structure by increasing nitrogen absorption, accelerating skeletal muscle growth and mobilizing body fat.http://genotropin 12mg

Visceral adipose tissue is especially sensitive to somatropin. In addition to stimulating lipolysis, somatropin reduces the flow of triglycerides into fat depots. Serum concentrations of IGF-1 (insulin-like growth factor type 1) and IGFBP-3 (IGF-binding protein type 3) are increased by  addition, the steps outlined below have been demonstrated.
—  Lipid metabolism . Somatropin stimulates low-density lipoprotein (LDL) cholesterol receptors in the liver and affects the lipid and lipoprotein profiles in the serum. In general, the use of somatropin in patients with growth hormone deficiency leads to a decrease in the concentration of LDL and apolipoprotein B. A decrease in total cholesterol levels is also possible.
—  Metabolism of carbohydrates . Somatropin increases insulin levels, but fasting glucose levels usually do not change. Children with hypopituitarism may have fasting hypoglycemia. Somatropin reverses this condition. genotropin 12mg
—  Water-salt metabolism . Growth hormone deficiency is associated with a decrease in blood plasma and tissue fluid volumes. Both of these indicators increase rapidly after treatment with somatropin. Somatropin promotes the retention of sodium, potassium and phosphorus in the body.
—  Bone metabolism . stimulates the renewal of skeletal bone tissue. In patients with growth hormone deficiency and osteoporosis, long-term treatment with somatropin leads to increased mineral composition and bone density at supporting sites.
—  Physical endurance . Long-term treatment with somatropin increases muscle strength and physical endurance. Somatropin also increases cardiac output, but the mechanism of this effect is not yet clear. A decrease in peripheral vascular resistance may play a certain role in this.
In clinical studies in short children born small for gestational age, doses ranging from 0.033 to 0.067 mg/kg body weight per day were used until final height was achieved. In 56 chronically treated patients who reached (almost reached) final height, the standard deviation (SD) for the mean change in height from the start of treatment was +1.90 SSD for the 0.033 mg/kg per day dose and +2.19 SSD for a dose of 0.067 mg/kg per day. Published data for infants born small for gestational age who were untreated and failed to achieve normal height spontaneously suggest late growth in the range of 0.5 VSD.
Pharmacokinetics .genotropin 12mg
Absorption . The bioavailability of somatropin administered subcutaneously is approximately 80% in both healthy volunteers and patients with growth hormone deficiency. A dose of 0.035 mg/kg of somatropin administered subcutaneously leads to the following ranges of Cmax and tmax values ​​in  blood plasma : 13-35 ng/ml and 3-6 hours, respectively.
Removal . The mean terminal half-life following intravenous use of somatropin in adults with growth hormone deficiency is approximately 0.4 hours. However, after subcutaneous administration, the half-life can be up to 2–3 hours. The observed difference may be due to slow absorption at the injection site following subcutaneous administration.genotropin 12mg
Subpopulations . The absolute bioavailability of somatropin when administered subcutaneously is the same in males and females.
Information on the pharmacokinetics of somatropin in elderly and pediatric patients, patients of different races, and patients with impaired renal or hepatic function or heart failure is lacking or incomplete.
Preclinical safety data .
No clinically relevant effects were observed in general toxicity, local tolerance or reproductive toxicity studies.
In vitro and  in vivo  genotoxicity studies regarding gene mutations and induction of chromosomal aberrations were negative.
In one in vitro study , increased chromosome fragility was observed in lymphocytes collected from patients following long-term treatment with somatropin and subsequent use of the additional radiomimetic drug bleomycin. The clinical significance of this fact is unclear.
In another study, no chromosomal abnormalities were detected in lymphocytes collected from patients after long-term treatment